BMY
Bristol-Myers Squibb Company trades as BMY and has a market capitalization of $114.08 B, making it the #132 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $48.19B, down 0.2% from the prior year and net income of $7.05B. This page tracks Bristol-Myers Squibb Company through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Bristol-Myers Squibb Company's revenue grew from $19.43B to $48.19B, a compound annual growth rate of 10.6%. Net profit margin compressed from 22.9% to 14.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Employee stock plan | S-8 | 2026-05-08 |
| Major company event | 8-K | 2026-05-08 |
| Insider trade | 4 | 2026-05-05 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-17 |
| Insider trade | 4 | 2026-04-02 |
Download this Press ReleasePDF Format (opens in new window)()
Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2025 on Thursday, February 5, 2026.
The largest companies sharing Bristol-Myers Squibb Company's SEC industry classification (pharmaceutical preparations).
Bristol-Myers Squibb Company (BMY) has a market capitalization of $114.08 B as of 2026-06-10, ranking #132 among US-listed companies.
Bristol-Myers Squibb Company reported revenue of $48.19B for fiscal year 2025, a decrease of 0.2% year over year.
Yes. Bristol-Myers Squibb Company reported net income of $7.05B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.